ASCO 2025 | Evaluating intravesical chemotherapy and BCG for enhanced outcomes in NMIBC
Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, discusses the potential role of combining intravesical chemotherapy with BCG in non-muscle-invasive bladder cancer (NMIBC). While BCG has been the standard for decades, emerging evidence suggests that pairing it with agents like mitomycin—particularly via electromotive drug administration—may enhance outcomes. Randomized data from Italian and Spanish groups demonstrate reduced recurrence and even survival benefits, though concerns about toxicity remain, especially with sequential administration. Despite promising meta-analyses, no adequately powered Phase III randomized trial has confirmed these findings, underscoring the need for further research to establish an optimized, tolerable chemoimmunotherapy regimen. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
